Skip to main content
. Author manuscript; available in PMC: 2016 Jan 1.
Published in final edited form as: Mol Cancer Res. 2014 Sep 3;13(1):50–62. doi: 10.1158/1541-7786.MCR-14-0440

Figure 1. A high-throughput screen identifies chelerythrine chloride as a selective inhibitor of TSC2-deficient angiomyolipoma-derived cells.

Figure 1

A) Design of screen. 621-101 cells were plated in 384-well plates and incubated overnight. DMSO or Rapamycin (20 nM) was added for a 2 hr pretreatment. The compounds were then pin transferred and the cells incubated for an additional 48 hours. ATP levels were assayed using CellTiter Glo and normalized to DMSO treatment. B) Top 6 hits from the screen showing relative ATP levels with and without Rapamycin. C) The chemical structure of chelerythrine chloride. D) Drug classes for 13 of the 32 agents with greater than 2-fold higher ATP levels when combined with Rapamycin vs. DMSO.